Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies
06 Mayo 2024 - 9:00AM
Business Wire
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”,
HKEX: 02315), a global biotechnology company focused on the
discovery of novel antibody-based therapeutics, today announced a
TCR-mimic antibody evaluation and potential licensing agreement
with BioCopy AG (“BioCopy”), a research-based biotechnology company
headquartered in Basel, Switzerland.
The agreement grants BioCopy access to fully human TCR-mimic
antibodies targeting an intracellular antigen generated by
Biocytogen’s proprietary RenTCR-mimicTM mice. BioCopy will conduct
an evaluation and retain the option to license these antibodies for
the development of novel cancer therapies.
“We are glad to provide BioCopy with our TCR-mimic antibodies,”
said Dr. Yuelei Shen, President and CEO of Biocytogen. “Our in vivo
matured TCR-mimic antibodies demonstrated favorable affinity and
excellent specificity. Combined with BioCopy’s expertise in
TCR-mimic antibody screening and engager development, we are
optimistic that our collaboration will generate novel drugs that
benefit cancer patients.”
BioCopy will use Biocytogen’s TCR-mimic antibodies and test them
against promising intracellular tumor associated antigens. Here,
BioCopy will use its automated end-to-end platform for the
optimization of multispecific biotherapeutics to further develop
these TCR-mimic antibodies into next-generation oncological
drugs.
About Biocytogen’s TCR-mimic Antibody Discovery
Platform
Biocytogen’s TCR-mimic platform focuses on the discovery of
fully human antibodies to intracellular targets that are presented
on the cell surface by MHC class I molecules. Leveraging
proprietary RenTCR-mimicTM (HLA/RenMab) mice and specialized
immunization protocols, Biocytogen’s platform is designed to
generate TCR-mimic antibodies that are highly specific for
peptide/HLA complexes and not HLA itself. Using a high-throughput
antibody screening platform, Biocytogen swiftly identifies
TCR-mimic antibodies with higher specificity and affinity than
endogenous TCRs derived from patients to overcome tumor immune
escape. Currently, antibody hits for multiple intracellular
targets, including TAAs, cancer-testis antigens, mutated protein
antigens, and viral protein antigens, are being evaluated in vivo
and in vitro. Fully human antibody sequences obtained from the
TCR-mimic platform can empower the development of T cell engagers,
bispecific/multispecific antibodies, and CAR-T therapies.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that
drives the research and development of novel antibody-based drugs
with innovative technologies. Founded on gene editing technology,
Biocytogen leverages genetically engineered proprietary RenMice®
(RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully
human monoclonal/bispecific/multispecific antibody discovery,
bispecific antibody-drug conjugate discovery, nanobody discovery
and TCR-mimic antibody discovery, and has established a sub-brand,
RenBiologicsTM, to explore global partnerships for an off-the-shelf
library of >400,000 fully human antibody sequences against
approximately 1000 targets for worldwide collaboration. As of
December 31, 2023, 103 therapeutic antibody and multiple clinical
asset co-development/out-licensing/transfer agreements and 47
target-nominated RenMice® licensing projects have been established
around the globe, including several partnerships with multinational
pharmaceutical companies (MNCs). Biocytogen pioneered the
generation of drug target knock-in humanized models for preclinical
research, and currently provides a few thousand off-the-shelf
animal and cell models under the company’s sub-brand, BioMiceTM,
along with preclinical pharmacology and gene-editing services for
clients worldwide. Headquartered in Beijing, Biocytogen has
branches in China (Haimen Jiangsu, Shanghai), the USA (Boston, San
Francisco), and Germany (Heidelberg). For more information, please
visit http://en.biocytogen.com.cn.
About BioCopy
BioCopy is a multinational company headquartered in Switzerland
with a state-of-the-art R&D facility in Germany. The company
focuses on biotherapeutic drug discovery and development using
their end-to-end automated, AI-powered platform. BioCopy is
convinced that cancer can be cured with ingenuity and AI, supported
by the extraordinary power of our body’s own immune system. With
the company’s unique platform, BioCopy is working continuously to
develop next-generation biotherapeutic drug candidates with
unprecedented efficacy and safety, transforming today’s
pharmaceutical industries.
Website: www.biocopy.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240506586492/en/
Biocytogen Antibody assets and platforms:
BD-Licensing@biocytogen.com Media: pr@bbctg.com.cn